There was no difference in mean disease duration (p = 0.07) or time interval between disease-onset and CSF analysis (p = 0.79), whereas the mean time interval between CSF analysis and death was longer in the AD group compared to FTLD-Tau (1.4 year difference, post-hoc p = 0.04) and FTLD-TDP (2.4 year difference, post-hoc p = 0.01). This evidence concerns the gene MAPT and Alzheimer disease.